Clinical Pharmacology & Therapeutics

1. A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

   Clinical Pharmacology &Therapeutics, EarlyView.

2. In This Issue

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1404-1404, June 2026.

3. In This Issue

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1405-1406, June 2026.

4. ASCPT News

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1407-1411, June 2026.

5. Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1401-1403, June 2026.

6. Issue Information

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1393-1398, June 2026.

7. Correction to “Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update”

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1671-1672, June 2026.

8. Correction to “Real‐World Outcomes of Pembrolizumab Monotherapy in Metastatic Non‐Small Cell Lung Cancer by Age and Sex: A National Population‐Based Study in Australia”

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1673-1673, June 2026.

9. Comparing the Efficacy of Various Treatment Strategies for Patients With Advanced Triple‐Negative Breast Cancer: An Umbrella Review

   Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1416-1430, June 2026.

10. Safety and Efficacy of Colchicine across the Spectrum of Coronary Artery Disease: A Systematic Review and Meta‐Analysis of 20 Randomized Trials

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1431-1439, June 2026.

11. TMDD Modeling for Antibodies Directed Against Soluble Targets: Parameter Values for De Novo Modeling and Simulation From Experimental Data

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1440-1459, June 2026.

12. Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof‐of‐Principle Analysis

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1460-1465, June 2026.

13. Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.

14. Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1485-1493, June 2026.

15. Structure‐Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1662-1670, June 2026.

16. Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1494-1502, June 2026.

17. Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1503-1513, June 2026.

18. Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.

19. More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.

20. Building a Robust Investigator‐Initiated Platform: The I‐CARE Experience

    Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1537-1546, June 2026.